Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation, announced that the Anesthetic and Analgesic Drug Products Advisory Committee of the U.S. FDA will hold a meeting on January 10, 2025, to review data supporting the biologics license application (BLA) for SI-6603 (generic name: condoliase), an investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation (LDH) in adults.
“Treatment options for the millions of Americans who suffer from radicular leg pain associated with lumbar disc herniation each year are currently limited to conservative pain management and physical therapy or surgery,” said Brent Ragans, President, Ferring Pharmaceuticals, U.S. “This represents a significant unmet patient need, and Ferring, in partnership with Seikagaku, is working to address this treatment gap.”
The FDA will live stream the advisory committee meeting and a webcast of the meeting will also be available on the FDA website.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!